Aura Biosciences, Inc. (AURA) Stock Competitors & Peer Comparison
See (AURA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AURA | $6.12 | -3.62% | 392.3M | -3.57 | -$1.71 | N/A |
| NVO | $42.81 | +1.47% | 190.1B | 10.04 | $4.26 | +4.19% |
| VRTX | $435.71 | -2.26% | 110.5B | 25.88 | $16.83 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $601.65 | -2.36% | 62B | 14.68 | $40.99 | +0.60% |
| ARGX | $862.18 | -2.47% | 53.4B | 38.30 | $22.51 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $291.22 | -2.17% | 38.9B | 73.40 | $3.97 | N/A |
| RVMD | $144.19 | -3.58% | 30.7B | -20.34 | -$7.09 | N/A |
| RPRX | $54.52 | -2.00% | 23.5B | 28.69 | $1.90 | +1.66% |
Stock Comparison
AURA vs NVO Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, NVO has a market cap of 190.1B. Regarding current trading prices, AURA is priced at $6.12, while NVO trades at $42.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas NVO's P/E ratio is 10.04. In terms of profitability, AURA's ROE is -0.78%, compared to NVO's ROE of +0.66%. Regarding short-term risk, AURA is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check NVO's competition here
AURA vs VRTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, VRTX has a market cap of 110.5B. Regarding current trading prices, AURA is priced at $6.12, while VRTX trades at $435.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas VRTX's P/E ratio is 25.88. In terms of profitability, AURA's ROE is -0.78%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, AURA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check VRTX's competition here
AURA vs VRNA Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, AURA is priced at $6.12, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas VRNA's P/E ratio is -102.80. In terms of profitability, AURA's ROE is -0.78%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, AURA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check VRNA's competition here
AURA vs REGN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, REGN has a market cap of 62B. Regarding current trading prices, AURA is priced at $6.12, while REGN trades at $601.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas REGN's P/E ratio is 14.68. In terms of profitability, AURA's ROE is -0.78%, compared to REGN's ROE of +0.14%. Regarding short-term risk, AURA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check REGN's competition here
AURA vs ARGX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ARGX has a market cap of 53.4B. Regarding current trading prices, AURA is priced at $6.12, while ARGX trades at $862.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ARGX's P/E ratio is 38.30. In terms of profitability, AURA's ROE is -0.78%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, AURA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ARGX's competition here
AURA vs SGEN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, AURA is priced at $6.12, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas SGEN's P/E ratio is -57.19. In terms of profitability, AURA's ROE is -0.78%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, AURA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check SGEN's competition here
AURA vs ALNY Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ALNY has a market cap of 38.9B. Regarding current trading prices, AURA is priced at $6.12, while ALNY trades at $291.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ALNY's P/E ratio is 73.40. In terms of profitability, AURA's ROE is -0.78%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, AURA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ALNY's competition here
AURA vs RVMD Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RVMD has a market cap of 30.7B. Regarding current trading prices, AURA is priced at $6.12, while RVMD trades at $144.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RVMD's P/E ratio is -20.34. In terms of profitability, AURA's ROE is -0.78%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, AURA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check RVMD's competition here
AURA vs RPRX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RPRX has a market cap of 23.5B. Regarding current trading prices, AURA is priced at $6.12, while RPRX trades at $54.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RPRX's P/E ratio is 28.69. In terms of profitability, AURA's ROE is -0.78%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, AURA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check RPRX's competition here
AURA vs UTHR Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, AURA is priced at $6.12, while UTHR trades at $544.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas UTHR's P/E ratio is 20.11. In terms of profitability, AURA's ROE is -0.78%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, AURA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check UTHR's competition here
AURA vs BNTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, BNTX has a market cap of 21.8B. Regarding current trading prices, AURA is priced at $6.12, while BNTX trades at $86.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas BNTX's P/E ratio is -14.65. In terms of profitability, AURA's ROE is -0.78%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, AURA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check BNTX's competition here
AURA vs INCY Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, INCY has a market cap of 21.1B. Regarding current trading prices, AURA is priced at $6.12, while INCY trades at $105.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas INCY's P/E ratio is 14.89. In terms of profitability, AURA's ROE is -0.78%, compared to INCY's ROE of +0.29%. Regarding short-term risk, AURA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check INCY's competition here
AURA vs ROIV Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ROIV has a market cap of 20.4B. Regarding current trading prices, AURA is priced at $6.12, while ROIV trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ROIV's P/E ratio is -52.61. In terms of profitability, AURA's ROE is -0.78%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, AURA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ROIV's competition here
AURA vs BGNE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, AURA is priced at $6.12, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas BGNE's P/E ratio is -22.55. In terms of profitability, AURA's ROE is -0.78%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, AURA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check BGNE's competition here
AURA vs INSM Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, INSM has a market cap of 19.9B. Regarding current trading prices, AURA is priced at $6.12, while INSM trades at $91.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas INSM's P/E ratio is -15.95. In terms of profitability, AURA's ROE is -0.78%, compared to INSM's ROE of -1.30%. Regarding short-term risk, AURA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check INSM's competition here
AURA vs DNA-WT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, AURA is priced at $6.12, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, AURA's ROE is -0.78%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, AURA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check DNA-WT's competition here
AURA vs MRNA Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MRNA has a market cap of 18.2B. Regarding current trading prices, AURA is priced at $6.12, while MRNA trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MRNA's P/E ratio is -5.64. In terms of profitability, AURA's ROE is -0.78%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, AURA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check MRNA's competition here
AURA vs NBIX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, AURA is priced at $6.12, while NBIX trades at $160.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas NBIX's P/E ratio is 24.71. In terms of profitability, AURA's ROE is -0.78%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, AURA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check NBIX's competition here
AURA vs GMAB Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, GMAB has a market cap of 15B. Regarding current trading prices, AURA is priced at $6.12, while GMAB trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas GMAB's P/E ratio is 18.55. In terms of profitability, AURA's ROE is -0.78%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, AURA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check GMAB's competition here
AURA vs JAZZ Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, JAZZ has a market cap of 14.4B. Regarding current trading prices, AURA is priced at $6.12, while JAZZ trades at $229.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas JAZZ's P/E ratio is 1913.58. In terms of profitability, AURA's ROE is -0.78%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, AURA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check JAZZ's competition here
AURA vs EXEL Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, EXEL has a market cap of 13.2B. Regarding current trading prices, AURA is priced at $6.12, while EXEL trades at $52.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas EXEL's P/E ratio is 17.41. In terms of profitability, AURA's ROE is -0.78%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, AURA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check EXEL's competition here
AURA vs BBIO Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, AURA is priced at $6.12, while BBIO trades at $67.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas BBIO's P/E ratio is -17.93. In terms of profitability, AURA's ROE is -0.78%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, AURA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check BBIO's competition here
AURA vs ASND Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ASND has a market cap of 13B. Regarding current trading prices, AURA is priced at $6.12, while ASND trades at $209.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ASND's P/E ratio is 24.05. In terms of profitability, AURA's ROE is -0.78%, compared to ASND's ROE of -56.42%. Regarding short-term risk, AURA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ASND's competition here
AURA vs AXSM Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, AXSM has a market cap of 12.7B. Regarding current trading prices, AURA is priced at $6.12, while AXSM trades at $246.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas AXSM's P/E ratio is -66.22. In terms of profitability, AURA's ROE is -0.78%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, AURA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check AXSM's competition here
AURA vs KRTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, AURA is priced at $6.12, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas KRTX's P/E ratio is -28.09. In terms of profitability, AURA's ROE is -0.78%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, AURA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check KRTX's competition here
AURA vs IONS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, AURA is priced at $6.12, while IONS trades at $73.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas IONS's P/E ratio is -36.48. In terms of profitability, AURA's ROE is -0.78%, compared to IONS's ROE of -0.59%. Regarding short-term risk, AURA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check IONS's competition here
AURA vs RNAM Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, AURA is priced at $6.12, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RNAM's P/E ratio is -17.39. In terms of profitability, AURA's ROE is -0.78%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, AURA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check RNAM's competition here
AURA vs MDGL Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MDGL has a market cap of 10.9B. Regarding current trading prices, AURA is priced at $6.12, while MDGL trades at $471.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MDGL's P/E ratio is -34.92. In terms of profitability, AURA's ROE is -0.78%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, AURA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check MDGL's competition here
AURA vs BMRN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, AURA is priced at $6.12, while BMRN trades at $56.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas BMRN's P/E ratio is 40.41. In terms of profitability, AURA's ROE is -0.78%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, AURA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check BMRN's competition here
AURA vs SMMT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, AURA is priced at $6.12, while SMMT trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas SMMT's P/E ratio is -8.21. In terms of profitability, AURA's ROE is -0.78%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, AURA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check SMMT's competition here
AURA vs ARWR Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ARWR has a market cap of 10B. Regarding current trading prices, AURA is priced at $6.12, while ARWR trades at $70.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ARWR's P/E ratio is -31.16. In terms of profitability, AURA's ROE is -0.78%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, AURA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check ARWR's competition here
AURA vs RXDX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, AURA is priced at $6.12, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RXDX's P/E ratio is -56.47. In terms of profitability, AURA's ROE is -0.78%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, AURA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check RXDX's competition here
AURA vs KRYS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, AURA is priced at $6.12, while KRYS trades at $312.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas KRYS's P/E ratio is 41.77. In terms of profitability, AURA's ROE is -0.78%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, AURA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check KRYS's competition here
AURA vs NUVL Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, AURA is priced at $6.12, while NUVL trades at $123.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas NUVL's P/E ratio is -20.35. In terms of profitability, AURA's ROE is -0.78%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, AURA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check NUVL's competition here
AURA vs IMGN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, AURA is priced at $6.12, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas IMGN's P/E ratio is -111.55. In terms of profitability, AURA's ROE is -0.78%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, AURA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check IMGN's competition here
AURA vs CORT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CORT has a market cap of 8.4B. Regarding current trading prices, AURA is priced at $6.12, while CORT trades at $78.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CORT's P/E ratio is 223.20. In terms of profitability, AURA's ROE is -0.78%, compared to CORT's ROE of +0.08%. Regarding short-term risk, AURA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check CORT's competition here
AURA vs HALO Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, AURA is priced at $6.12, while HALO trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas HALO's P/E ratio is 24.74. In terms of profitability, AURA's ROE is -0.78%, compared to HALO's ROE of +1.26%. Regarding short-term risk, AURA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check HALO's competition here
AURA vs BPMC Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, AURA is priced at $6.12, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas BPMC's P/E ratio is -51.58. In terms of profitability, AURA's ROE is -0.78%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, AURA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check BPMC's competition here
AURA vs CYTK Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CYTK has a market cap of 8.3B. Regarding current trading prices, AURA is priced at $6.12, while CYTK trades at $67.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CYTK's P/E ratio is -9.79. In terms of profitability, AURA's ROE is -0.78%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, AURA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CYTK's competition here
AURA vs TECH Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, AURA is priced at $6.12, while TECH trades at $52.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas TECH's P/E ratio is 75.00. In terms of profitability, AURA's ROE is -0.78%, compared to TECH's ROE of +0.05%. Regarding short-term risk, AURA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check TECH's competition here
AURA vs CERE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, AURA is priced at $6.12, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CERE's P/E ratio is -16.47. In terms of profitability, AURA's ROE is -0.78%, compared to CERE's ROE of -0.72%. Regarding short-term risk, AURA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CERE's competition here
AURA vs MTSR Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, AURA is priced at $6.12, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MTSR's P/E ratio is -23.58. In terms of profitability, AURA's ROE is -0.78%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, AURA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check MTSR's competition here
AURA vs IBRX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, AURA is priced at $6.12, while IBRX trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas IBRX's P/E ratio is -7.93. In terms of profitability, AURA's ROE is -0.78%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, AURA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check IBRX's competition here
AURA vs ALKS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ALKS has a market cap of 7.3B. Regarding current trading prices, AURA is priced at $6.12, while ALKS trades at $43.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ALKS's P/E ratio is 48.72. In terms of profitability, AURA's ROE is -0.78%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, AURA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ALKS's competition here
AURA vs TGTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, TGTX has a market cap of 7.1B. Regarding current trading prices, AURA is priced at $6.12, while TGTX trades at $46.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas TGTX's P/E ratio is 16.30. In terms of profitability, AURA's ROE is -0.78%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, AURA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check TGTX's competition here
AURA vs MRUS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, AURA is priced at $6.12, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MRUS's P/E ratio is -17.05. In terms of profitability, AURA's ROE is -0.78%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, AURA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check MRUS's competition here
AURA vs PTGX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, PTGX has a market cap of 6.8B. Regarding current trading prices, AURA is priced at $6.12, while PTGX trades at $105.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas PTGX's P/E ratio is -58.44. In terms of profitability, AURA's ROE is -0.78%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, AURA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check PTGX's competition here
AURA vs ACLX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, AURA is priced at $6.12, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ACLX's P/E ratio is -28.27. In terms of profitability, AURA's ROE is -0.78%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, AURA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ACLX's competition here
AURA vs RETA Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, AURA is priced at $6.12, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RETA's P/E ratio is -66.29. In terms of profitability, AURA's ROE is -0.78%, compared to RETA's ROE of +0.47%. Regarding short-term risk, AURA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check RETA's competition here
AURA vs PCVX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, PCVX has a market cap of 6.6B. Regarding current trading prices, AURA is priced at $6.12, while PCVX trades at $45.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas PCVX's P/E ratio is -6.74. In terms of profitability, AURA's ROE is -0.78%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, AURA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check PCVX's competition here
AURA vs LEGN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, LEGN has a market cap of 6.4B. Regarding current trading prices, AURA is priced at $6.12, while LEGN trades at $34.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas LEGN's P/E ratio is -25.26. In terms of profitability, AURA's ROE is -0.78%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, AURA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check LEGN's competition here
AURA vs KYMR Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, KYMR has a market cap of 6.4B. Regarding current trading prices, AURA is priced at $6.12, while KYMR trades at $78.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas KYMR's P/E ratio is -21.85. In terms of profitability, AURA's ROE is -0.78%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, AURA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check KYMR's competition here
AURA vs ABVX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, AURA is priced at $6.12, while ABVX trades at $98.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ABVX's P/E ratio is -18.29. In terms of profitability, AURA's ROE is -0.78%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, AURA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ABVX's competition here
AURA vs IMVT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, IMVT has a market cap of 6.4B. Regarding current trading prices, AURA is priced at $6.12, while IMVT trades at $31.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas IMVT's P/E ratio is -11.26. In terms of profitability, AURA's ROE is -0.78%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, AURA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check IMVT's competition here
AURA vs CNTA Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, AURA is priced at $6.12, while CNTA trades at $39.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CNTA's P/E ratio is -22.30. In terms of profitability, AURA's ROE is -0.78%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, AURA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CNTA's competition here
AURA vs PTCT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, AURA is priced at $6.12, while PTCT trades at $73.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas PTCT's P/E ratio is -28.88. In terms of profitability, AURA's ROE is -0.78%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, AURA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check PTCT's competition here
AURA vs RYTM Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, AURA is priced at $6.12, while RYTM trades at $85.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RYTM's P/E ratio is -27.38. In terms of profitability, AURA's ROE is -0.78%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, AURA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check RYTM's competition here
AURA vs LQDA Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, LQDA has a market cap of 5.8B. Regarding current trading prices, AURA is priced at $6.12, while LQDA trades at $65.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas LQDA's P/E ratio is 383.82. In terms of profitability, AURA's ROE is -0.78%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, AURA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check LQDA's competition here
AURA vs CDTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, AURA is priced at $6.12, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CDTX's P/E ratio is -19.77. In terms of profitability, AURA's ROE is -0.78%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, AURA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CDTX's competition here
AURA vs ABCM Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, AURA is priced at $6.12, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, AURA's ROE is -0.78%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, AURA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ABCM's competition here
AURA vs ISEE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, AURA is priced at $6.12, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ISEE's P/E ratio is -22.44. In terms of profitability, AURA's ROE is -0.78%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, AURA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ISEE's competition here
AURA vs BLTE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, AURA is priced at $6.12, while BLTE trades at $136.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas BLTE's P/E ratio is -53.83. In terms of profitability, AURA's ROE is -0.78%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, AURA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check BLTE's competition here
AURA vs COGT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, AURA is priced at $6.12, while COGT trades at $31.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas COGT's P/E ratio is -14.46. In terms of profitability, AURA's ROE is -0.78%, compared to COGT's ROE of -0.83%. Regarding short-term risk, AURA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check COGT's competition here
AURA vs FBIOX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, AURA is priced at $6.12, while FBIOX trades at $24.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas FBIOX's P/E ratio is N/A. In terms of profitability, AURA's ROE is -0.78%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, AURA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check FBIOX's competition here
AURA vs SRRK Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, AURA is priced at $6.12, while SRRK trades at $44.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas SRRK's P/E ratio is -12.78. In terms of profitability, AURA's ROE is -0.78%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, AURA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check SRRK's competition here
AURA vs APLS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, AURA is priced at $6.12, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas APLS's P/E ratio is 38.35. In terms of profitability, AURA's ROE is -0.78%, compared to APLS's ROE of +0.40%. Regarding short-term risk, AURA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check APLS's competition here
AURA vs APGE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, AURA is priced at $6.12, while APGE trades at $82.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas APGE's P/E ratio is -19.10. In terms of profitability, AURA's ROE is -0.78%, compared to APGE's ROE of -0.33%. Regarding short-term risk, AURA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check APGE's competition here
AURA vs PRAX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, PRAX has a market cap of 5.1B. Regarding current trading prices, AURA is priced at $6.12, while PRAX trades at $240.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas PRAX's P/E ratio is -17.97. In terms of profitability, AURA's ROE is -0.78%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, AURA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check PRAX's competition here
AURA vs LGND Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, LGND has a market cap of 5B. Regarding current trading prices, AURA is priced at $6.12, while LGND trades at $248.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas LGND's P/E ratio is 32.32. In terms of profitability, AURA's ROE is -0.78%, compared to LGND's ROE of +0.16%. Regarding short-term risk, AURA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check LGND's competition here
AURA vs CAI Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, AURA is priced at $6.12, while CAI trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CAI's P/E ratio is -6.22. In terms of profitability, AURA's ROE is -0.78%, compared to CAI's ROE of +0.06%. Regarding short-term risk, AURA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check CAI's competition here
AURA vs CGON Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CGON has a market cap of 4.8B. Regarding current trading prices, AURA is priced at $6.12, while CGON trades at $54.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CGON's P/E ratio is -23.47. In terms of profitability, AURA's ROE is -0.78%, compared to CGON's ROE of -0.23%. Regarding short-term risk, AURA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check CGON's competition here
AURA vs TERN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, AURA is priced at $6.12, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas TERN's P/E ratio is -51.41. In terms of profitability, AURA's ROE is -0.78%, compared to TERN's ROE of -0.20%. Regarding short-term risk, AURA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check TERN's competition here
AURA vs CRSP Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, AURA is priced at $6.12, while CRSP trades at $49.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CRSP's P/E ratio is -8.01. In terms of profitability, AURA's ROE is -0.78%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, AURA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CRSP's competition here
AURA vs MIRM Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, AURA is priced at $6.12, while MIRM trades at $94.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MIRM's P/E ratio is -6.91. In terms of profitability, AURA's ROE is -0.78%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, AURA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check MIRM's competition here
AURA vs FOLD Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, AURA is priced at $6.12, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas FOLD's P/E ratio is -161.00. In terms of profitability, AURA's ROE is -0.78%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, AURA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check FOLD's competition here
AURA vs SYRE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, AURA is priced at $6.12, while SYRE trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas SYRE's P/E ratio is -35.42. In terms of profitability, AURA's ROE is -0.78%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, AURA is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check SYRE's competition here
AURA vs AKRO Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, AURA is priced at $6.12, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas AKRO's P/E ratio is -14.57. In terms of profitability, AURA's ROE is -0.78%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, AURA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check AKRO's competition here
AURA vs ALPN Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, AURA is priced at $6.12, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ALPN's P/E ratio is -101.52. In terms of profitability, AURA's ROE is -0.78%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, AURA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ALPN's competition here
AURA vs TVTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, TVTX has a market cap of 4.3B. Regarding current trading prices, AURA is priced at $6.12, while TVTX trades at $46.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas TVTX's P/E ratio is -93.48. In terms of profitability, AURA's ROE is -0.78%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, AURA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check TVTX's competition here
AURA vs CELC Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, AURA is priced at $6.12, while CELC trades at $88.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CELC's P/E ratio is -22.59. In terms of profitability, AURA's ROE is -0.78%, compared to CELC's ROE of -2.45%. Regarding short-term risk, AURA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check CELC's competition here
AURA vs OPT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, AURA is priced at $6.12, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas OPT's P/E ratio is -1.52. In terms of profitability, AURA's ROE is -0.78%, compared to OPT's ROE of +1.09%. Regarding short-term risk, AURA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check OPT's competition here
AURA vs ERAS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, AURA is priced at $6.12, while ERAS trades at $13.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ERAS's P/E ratio is -14.38. In terms of profitability, AURA's ROE is -0.78%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, AURA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ERAS's competition here
AURA vs MRTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, AURA is priced at $6.12, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MRTX's P/E ratio is -4.82. In terms of profitability, AURA's ROE is -0.78%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, AURA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check MRTX's competition here
AURA vs XENE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, AURA is priced at $6.12, while XENE trades at $51.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas XENE's P/E ratio is -10.92. In terms of profitability, AURA's ROE is -0.78%, compared to XENE's ROE of -0.49%. Regarding short-term risk, AURA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check XENE's competition here
AURA vs MANE Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, MANE has a market cap of 3.9B. Regarding current trading prices, AURA is priced at $6.12, while MANE trades at $92.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas MANE's P/E ratio is -35.09. In terms of profitability, AURA's ROE is -0.78%, compared to MANE's ROE of -0.95%. Regarding short-term risk, AURA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check MANE's competition here
AURA vs VCYT Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, AURA is priced at $6.12, while VCYT trades at $48.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas VCYT's P/E ratio is 44.60. In terms of profitability, AURA's ROE is -0.78%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, AURA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check VCYT's competition here
AURA vs CPRX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, AURA is priced at $6.12, while CPRX trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CPRX's P/E ratio is 18.12. In terms of profitability, AURA's ROE is -0.78%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, AURA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CPRX's competition here
AURA vs RYZB Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, AURA is priced at $6.12, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas RYZB's P/E ratio is -57.86. In terms of profitability, AURA's ROE is -0.78%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, AURA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check RYZB's competition here
AURA vs CBAY Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, AURA is priced at $6.12, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CBAY's P/E ratio is -32.81. In terms of profitability, AURA's ROE is -0.78%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, AURA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CBAY's competition here
AURA vs KNSA Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, AURA is priced at $6.12, while KNSA trades at $49.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas KNSA's P/E ratio is 54.14. In terms of profitability, AURA's ROE is -0.78%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, AURA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check KNSA's competition here
AURA vs ACAD Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, AURA is priced at $6.12, while ACAD trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas ACAD's P/E ratio is 9.61. In terms of profitability, AURA's ROE is -0.78%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, AURA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check ACAD's competition here
AURA vs CRNX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, AURA is priced at $6.12, while CRNX trades at $34.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas CRNX's P/E ratio is -6.67. In terms of profitability, AURA's ROE is -0.78%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, AURA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check CRNX's competition here
AURA vs EWTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, AURA is priced at $6.12, while EWTX trades at $32.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas EWTX's P/E ratio is -19.83. In terms of profitability, AURA's ROE is -0.78%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, AURA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check EWTX's competition here
AURA vs SWTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, AURA is priced at $6.12, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas SWTX's P/E ratio is -13.78. In terms of profitability, AURA's ROE is -0.78%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, AURA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check SWTX's competition here
AURA vs NAMS Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, AURA is priced at $6.12, while NAMS trades at $29.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas NAMS's P/E ratio is -16.48. In terms of profitability, AURA's ROE is -0.78%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, AURA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check NAMS's competition here
AURA vs TNGX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, TNGX has a market cap of 3.3B. Regarding current trading prices, AURA is priced at $6.12, while TNGX trades at $28.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas TNGX's P/E ratio is -34.55. In terms of profitability, AURA's ROE is -0.78%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, AURA is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check TNGX's competition here
AURA vs DNLI Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, AURA is priced at $6.12, while DNLI trades at $20.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas DNLI's P/E ratio is -7.16. In terms of profitability, AURA's ROE is -0.78%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, AURA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for AURA.Check DNLI's competition here
AURA vs VKTX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, VKTX has a market cap of 3.2B. Regarding current trading prices, AURA is priced at $6.12, while VKTX trades at $27.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas VKTX's P/E ratio is -6.69. In terms of profitability, AURA's ROE is -0.78%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, AURA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check VKTX's competition here
AURA vs TLX Comparison June 2026
AURA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AURA stands at 392.3M. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, AURA is priced at $6.12, while TLX trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AURA currently has a P/E ratio of -3.57, whereas TLX's P/E ratio is -472.00. In terms of profitability, AURA's ROE is -0.78%, compared to TLX's ROE of -0.02%. Regarding short-term risk, AURA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for AURA.Check TLX's competition here